Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.

In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelic Stock News Stories for the Week of January 18th – 24th, 2021.

Without further ado, let’s get started.

* Yahoo Finance readers, please click here to view the full article.

10. 17 Psychedelic Stocks Included in the World’s First Psychedelics ETF

It’s Official, Horizons ETFs Has Filed its Final Prospectus, and the First-Ever Psychedelics ETF is Set to Commence Trading Soon on the NEO Exchange

The Horizons Psychedelic Stock Index ETF PSYK is set to become the world’s first Exchange-Traded Fund (ETF) focused on the emerging Psychedelics sector. On Friday, Horizons ETFs announced that it filed its final prospectus and that the PSYK ETF units have received conditional approval to list on the NEO Exchange (NEO). The inaugural Psychedelics ETF will seek to replicate the performance of the North American Psychedelics Index and will include these 17 Psychedelic Stocks.

READ FULL PSYK ETF ARTICLE

9. Aurora Cannabis: Another Day, Another Dilution

Aurora Cannabis Investors Are a Resilient Lot

The Canadian Licensed Producer (LP) is notorious for diluting its shares via cash-raising efforts. Aurora Cannabis ACB has continually burnt a hole through its reserves, and the share count has ballooned over the years as it has attempted to put the fires out. Its latest move has involved another attempt to pad the coffers; On Thursday, the company announced a bought deal of $125 million, in which it has agreed to sell approximately 12 million units for $10.45 each.

READ FULL AURORA CANNABIS ARTICLE

8. MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

If Administered in Combination with LSD, MDMA May Increase Positive Subjective Drug Effects, Including Positive Mood and Empathy, and Reduce the Negative Emotions and Anxiety Sometimes Associated with LSD

MindMed MMEDF, a leading Psychedelic medicine biotech company, announced the start of the first-ever clinical trial measuring and evaluating MDMA and LSD used in combination in the human body. The trial will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland.

READ FULL MINDMED ARTICLE

7. Canopy Growth CEO on Launch of CBD Beverage Line Quatreau: ‘Our First Foray Into Mood Modulation’

Dubbed Quatreau, the Sparkling Waters Represent the Company’s First Incursion Into the CBD Beverages Market in Canada

Less than 48 hours after informing it would move its U.S. stock listing from the New York Stock Exchange (NYSE) to the NASDAQ Exchange, Canadian cannabis giant Canopy Growth CGC announced the launch of a new line of CBD-infused beverages.

READ FULL CANOPY GROWTH ARTICLE

6. Champignon Brands’ Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression

Third CRTCE Clinic Effectively Addresses the Unmet Need of Depression and Suicide

Champignon Brands SHRMF, Chairman and CEO Dr. Roger McIntyre announced the opening of a new Canadian Rapid Treatment Center of Excellence (CRTCE) clinic in Ottawa, Ontario. This third clinic joins the Mississauga and Toronto clinics (CRTCE Clinics) in addressing the unmet need of depression and suicide through novel Ketamine therapy treatment.

READ FULL CHAMPIGNON BRANDS ARTICLE

5. Unifor and Aleafia Health Enter Exclusive Agreement to Support Medical Cannabis Coverage for Members

The Agreement Supports a Historic Breakthrough in Access to Legal Cannabis in Canada

Unifor and Aleafia Health ALEAF, have entered into an exclusive 10-year agreement to support union members, retirees and their eligible dependents who receive medical Cannabis insurance coverage through Unifor’s collective bargaining agreements. “Unifor members across the country deserve access to the benefits of medical cannabis coverage through their benefits. As a union we will support our local bargaining committees to add this coverage where possible,” said Jerry Dias, Unifor National President.

READ FULL ALEAFIA ARTICLE

4. Why the Creso Pharma Share Price is Smoking the Market Today

Creso Pharma’s Stock is on the Move Following a Recent Announcement That the Company Secured a New Purchase Order for its Leading Range of Animal Health Products Anibidiol

According to the Creso Pharma COPHF press release, the order has come from its existing commercial partner, Virbac Switzerland, and is a repeat of a previous order. The order is valued at CHF171,000 (A$247,826) and is expected to be delivered to Virbac Switzerland in April 2021. Management notes that this adds to a number of orders that Creso Pharma has secured in the recent weeks including three for anibidiol valued at CHF277,000 (A$401,4491) from current commercial partners. The company expects to fulfil these orders during the current quarter, with the sale to be banked shortly after. In addition to this, Creso Pharma advised that it is also witnessing strong demand for its products in Latin America.

READ FULL CRESO PHARMA ARTICLE

3. COMPASS Pathways Receives Consensus Rating of “Buy” from Brokerages

Shares of COMPASS Pathways Have Been Given a Consensus Recommendation of “Buy” By the Six Brokerages That Are Covering the Company

One research analyst has rated Compass Pathways CMPS with a hold recommendation and five have issued a buy recommendation on CMPS stock. The average 1-year price target among brokerages that have covered the stock in the last year is $65.

• Cowen: “Outperform” Rating
• Berenberg Bank: “Buy” Rating and $50 Price Target
• Evercore ISI: “Outperform” Rating
• Canaccord Genuity: “Buy” Rating and $80 Price Target
• HC Wainwright: “Buy” Rating and $65 Price Target

READ FULL COMPASS PATHWAYS ARTICLE

2. With Democrats in Control, Investors Are High on Cannabis

Weed Businesses Are Counting on the Political Shift to Help Them Win Access to Financial Markets and Perhaps Even National Legalization of Pot

For Kim Rivers, chief executive officer of Florida-based Trulieve TRUL TCNNF, the beginning of the year is usually busy with strategy reviews or fielding calls about the state of the nascent industry. But almost overnight on Jan. 6, as Democrats cemented their hold on both Congress and the White House, interest in her company reached a new high. Suddenly the number of meetings lined up for her January investor conferences doubled, and the calls from investors and analysts skyrocketed.

READ FULL HIGH ON CANNABIS ARTICLE

1. Horizons ETFs to Launch World’s First Psychedelics-Focused ETF

PSYK Will Be the World’s First Exchange-Traded Fund Focused on the Emerging Psychedelics Opportunity Led By Life Science and Pharmaceutical Companies

Horizons ETFs Management (Canada) announced that it has filed its final prospectus to launch the Horizons Psychedelic Stock Index ETF PSYK. Units of PSYK have been conditionally approved for listing by the NEO Exchange and are slated to begin trading on January 27, 2021, under the ticker symbol PSYK.

READ FULL PSYCHEDELIC ETF ARTICLE

Photo by Next Green Wave on Unsplash